Payment overview · 2025
General Payments
$132.78
5 reported records · 4 companies
Healthcare provider profile · identity verified
Mohammad Irfan, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MONTGOMERY, AL · NPI 1023395696
Verified facts
What the public records show
CMS Open Payments records show Mohammad Irfan, M.D. received $132.78 in general payments during 2025 across 5 reported records.
INTUITIVE SURGICAL, INC. accounted for 33.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $44.92 | 33.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $42.10 | 31.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $23.64 | 17.8% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $22.12 | 16.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $132.78 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $44.92 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $42.10 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $23.64 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $23.64 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $22.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 66 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
66 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 431 | 139 |
| Amlodipine Besylate | Amlodipine Besylate | 419 | 141 |
| Levothyroxine Sodium | Levothyroxine Sodium | 280 | 88 |
| Losartan Potassium | Losartan Potassium | 254 | 82 |
| Meloxicam | Meloxicam | 251 | 78 |
| Pantoprazole Sodium | Pantoprazole Sodium | 216 | 74 |
| Furosemide | Furosemide | 185 | 78 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 175 | 55 |
| Carvedilol | Carvedilol | 162 | 61 |
| Metformin Hcl | Metformin Hcl | 159 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 148 | 46 |
| Omeprazole | Omeprazole | 146 | 51 |
| Lisinopril | Lisinopril | 144 | 49 |
| Trazodone Hcl | Trazodone Hcl | 139 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 135 | 51 |
| Potassium Chloride | Potassium Chloride | 134 | 60 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 125 | 59 |
| Clopidogrel | Clopidogrel Bisulfate | 123 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 111 | 42 |
| Famotidine | Famotidine | 103 | 37 |
| Hydralazine Hcl | Hydralazine Hcl | 100 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 97 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 95 | 37 |
| Azithromycin | Azithromycin | 93 | 71 |
| Prednisone | Prednisone | 92 | 76 |
| Cefdinir | Cefdinir | 90 | 84 |
| Donepezil Hcl | Donepezil Hcl | 83 | 23 |
| Atenolol | Atenolol | 79 | 22 |
| Alprazolam | Alprazolam | 78 | 17 |
| Ozempic | Semaglutide | 76 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 76 | 27 |
| Allopurinol | Allopurinol | 74 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 74 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 73 | 22 |
| Gabapentin | Gabapentin | 73 | 18 |
| Januvia | Sitagliptin Phosphate | 71 | 26 |
| Sertraline Hcl | Sertraline Hcl | 71 | 23 |
| Methylprednisolone | Methylprednisolone | 67 | 55 |
| Eliquis | Apixaban | 66 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | 21 |
| Montelukast Sodium | Montelukast Sodium | 65 | 24 |
| Clonidine Hcl | Clonidine Hcl | 63 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 61 | 26 |
| Ezetimibe | Ezetimibe | 60 | 22 |
| Mounjaro | Tirzepatide | 60 | 12 |
| Chlorthalidone | Chlorthalidone | 57 | 20 |
| Simvastatin | Simvastatin | 54 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 20 |
| Tramadol Hcl | Tramadol Hcl | 53 | 13 |
| Buspirone Hcl | Buspirone Hcl | 51 | 19 |
| Glipizide | Glipizide | 51 | 22 |
| Labetalol Hcl | Labetalol Hcl | 48 | 11 |
| Memantine Hcl | Memantine Hcl | 48 | 18 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 47 | 25 |
| Spironolactone | Spironolactone | 41 | 16 |
| Levofloxacin | Levofloxacin | 40 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 11 |
| Mirtazapine | Mirtazapine | 40 | suppressed |
| Pregabalin | Pregabalin | 40 | suppressed |
| Ondansetron Odt | Ondansetron | 39 | 21 |
| Telmisartan | Telmisartan | 39 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | suppressed |
| Fluconazole | Fluconazole | 37 | 24 |
| Bupropion Xl | Bupropion Hcl | 36 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | 14 |
| Lovastatin | Lovastatin | 32 | suppressed |
| Ramipril | Ramipril | 32 | 15 |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | 11 |
| Trulicity | Dulaglutide | 29 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Bumetanide | Bumetanide | 28 | 13 |
| Cephalexin | Cephalexin | 28 | 20 |
| Nifedipine Er | Nifedipine | 28 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Jardiance | Empagliflozin | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 12 |
| Mupirocin | Mupirocin | 26 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Linzess | Linaclotide | 25 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | 11 |
| Glipizide Er | Glipizide | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Klor-Con 10 | Potassium Chloride | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 18 |
| Clonazepam | Clonazepam | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Praluent Pen | Alirocumab | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Nystatin | Nystatin | 16 | 12 |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 14 |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Gemtesa | Vibegron | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Livalo | Pitavastatin Calcium | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Ofloxacin | Ofloxacin | 12 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | 11 |
| Belsomra | Suvorexant | 11 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $132.78 · 5 records | INTUITIVE SURGICAL, INC. | AIRSUPRA, Da Vinci Surgical System, ELIQUIS, OTEZLA, REPATHA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error